153 related articles for article (PubMed ID: 35486228)
1. Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer-INCAGI004.
Araujo RO; Vieira FM; Victorino AP; Torres C; Martins I; Guaraldi S; Valadão M; Linhares E; Ferreira CG; Thuler LC
Support Care Cancer; 2022 Aug; 30(8):6557-6572. PubMed ID: 35486228
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of neoadjuvant chemoradiotherapy followed by sphincter-preserving resection on anal sphincter function in relation to quality of life among locally advanced rectal cancer patients: a cross-sectional analysis.
Ozgen Z; Ozden S; Atasoy BM; Ozyurt H; Gencosmanoglu R; Imeryuz N
Radiat Oncol; 2015 Aug; 10():168. PubMed ID: 26264590
[TBL] [Abstract][Full Text] [Related]
3. [Quality of life of patients with locally advanced rectal cancer after neoadjuvant therapy and sphincter-preserving surgery].
Shi WK; Li YH; Qiu XY; Xiao Y; Zhou JL; Wu B; Lin GL
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Apr; 25(4):348-356. PubMed ID: 35461204
[No Abstract] [Full Text] [Related]
4. Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.
Velenik V; Zadnik V; Omejc M; Grosek J; Tuta M
Radiol Oncol; 2020 Aug; 54(4):461-469. PubMed ID: 32738130
[TBL] [Abstract][Full Text] [Related]
5. Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.
Sclafani F; Peckitt C; Cunningham D; Tait D; Giralt J; Glimelius B; Keränen SR; Bateman A; Hickish T; Tabernero J; Thomas J; Brown G; Oates J; Chau I
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):303-12. PubMed ID: 26031368
[TBL] [Abstract][Full Text] [Related]
6. Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
Kang MK; Park SY; Park JS; Kim HJ; Kim JG; Kang BW; Baek JH; Cho SH; Seo AN; Kim DW; Kim J; Baek SJ; Kim JH; Kim JY; Ha GW; Park EJ; Park IJ; Kim CH; Kang H; Choi GS
BMC Cancer; 2023 Nov; 23(1):1059. PubMed ID: 37923987
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
[TBL] [Abstract][Full Text] [Related]
8. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Rahma OE; Yothers G; Hong TS; Russell MM; You YN; Parker W; Jacobs SA; Colangelo LH; Lucas PC; Gollub MJ; Hall WA; Kachnic LA; Vijayvergia N; O'Rourke MA; Faller BA; Valicenti RK; Schefter TE; George S; Kainthla R; Stella PJ; Sigurdson E; Wolmark N; George TJ
JAMA Oncol; 2021 Aug; 7(8):1225-1230. PubMed ID: 34196693
[TBL] [Abstract][Full Text] [Related]
9. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
10. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
[TBL] [Abstract][Full Text] [Related]
11. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study.
Senyurek S; Saglam S; Saglam EK; Yanar H; Gok K; Tastekin D; Akbas CK; Sakin ND; Kartal GD; Balik E; Keskin M; Sanli Y; Gulluoglu M; Akgun Z
Oncol Res; 2023; 31(5):689-696. PubMed ID: 37547762
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
Fokas E; Schlenska-Lange A; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Kirste S; Jacobasch L; Allgäuer M; Flentje M; Germer CT; Grützmann R; Hildebrandt G; Schwarzbach M; Bechstein WO; Sülberg H; Friede T; Gaedcke J; Ghadimi M; Hofheinz RD; Rödel C;
JAMA Oncol; 2022 Jan; 8(1):e215445. PubMed ID: 34792531
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
Hanna CR; O'Cathail SM; Graham JS; Saunders M; Samuel L; Harrison M; Devlin L; Edwards J; Gaya DR; Kelly CA; Lewsley LA; Maka N; Morrison P; Dinnett L; Dillon S; Gourlay J; Platt JJ; Thomson F; Adams RA; Roxburgh CSD
Radiat Oncol; 2021 Aug; 16(1):163. PubMed ID: 34446053
[TBL] [Abstract][Full Text] [Related]
15. Evolving role of neoadjuvant therapy in rectal cancer.
Schrag D
Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer.
Paszt A; Ottlakan A; Abraham S; Simonka Z; Vas M; Maraz A; Szepes Z; Tiszlavicz L; Nyari T; Olah J; Lazar G
Pathol Oncol Res; 2022; 28():1610722. PubMed ID: 36567978
[No Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
O'Connell MJ; Colangelo LH; Beart RW; Petrelli NJ; Allegra CJ; Sharif S; Pitot HC; Shields AF; Landry JC; Ryan DP; Parda DS; Mohiuddin M; Arora A; Evans LS; Bahary N; Soori GS; Eakle J; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Wozniak TF; Roh MS; Yothers G; Wolmark N
J Clin Oncol; 2014 Jun; 32(18):1927-34. PubMed ID: 24799484
[TBL] [Abstract][Full Text] [Related]
19. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.
Azria D; Doyen J; Jarlier M; Martel-Lafay I; Hennequin C; Etienne P; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah J; Mahé M; Bécouarn Y; Dupuis O; Lledo G; Seitz J; Bedenne L; Gourgou-Bourgade S; Juzyna B; Conroy T; Gérard J
Ann Oncol; 2017 Oct; 28(10):2436-2442. PubMed ID: 28961836
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
